[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Generic_Tina Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1511682976639119365.png) @Generic_Tina Tina Banerjee

Tina Banerjee posts on X about japan, $6b, gilead sciences, sanofi the most. They currently have XX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::1511682976639119365/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:interactions.svg)

- X Week XXX +70%
- X Month XXX -XXXX%
- X Months XXXXX +100%
- X Year XXXXXX +304%

### Mentions: X [#](/creator/twitter::1511682976639119365/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:posts_active.svg)

- X Week XX +50%
- X Month XX -XX%
- X Months XXX +55%
- X Year XXX +251%

### Followers: XX [#](/creator/twitter::1511682976639119365/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:followers.svg)

- X Week XX no change
- X Month XX -XXXX%
- X Months XX +26%

### CreatorRank: undefined [#](/creator/twitter::1511682976639119365/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1511682976639119365/influence)
---

**Social category influence**
[finance](/list/finance)  XXXX% [countries](/list/countries)  XXXX% [stocks](/list/stocks)  X% [travel destinations](/list/travel-destinations)  XXX%

**Social topic influence**
[japan](/topic/japan) 1%, [$6b](/topic/$6b) 0.5%, [gilead sciences](/topic/gilead-sciences) 0.5%, [sanofi](/topic/sanofi) 0.5%, [has been](/topic/has-been) 0.5%, [$8750t](/topic/$8750t) 0.5%, [approved](/topic/approved) 0.5%, [acquisition](/topic/acquisition) 0.5%, [uplift](/topic/uplift) 0.5%, [$206m](/topic/$206m) XXX%

**Top accounts mentioned or mentioned by**
[@smartkarma](/creator/undefined)

**Top assets mentioned**
[Gilead Sciences, Inc. (GILD)](/topic/gilead-sciences) [Sanofi (SNY)](/topic/sanofi)
### Top Social Posts [#](/creator/twitter::1511682976639119365/posts)
---
Top posts by engagements in the last XX hours

"3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707 resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707 and strong financial performance are expected ahead"  
[X Link](https://x.com/Generic_Tina/status/1939845218901402107) [@Generic_Tina](/creator/x/Generic_Tina) 2025-07-01T00:35Z XX followers, 1037 engagements


"Daiichi Sankyos label expansion application for Enhertu has been accepted by FDA. Hanmi Pharm entered into global licensing agreement with Gilead Sciences. Boryung is acquiring Taxotere from Sanofi"  
[X Link](https://x.com/Generic_Tina/status/1974634457497030897) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-05T00:35Z XX followers, XX engagements


"SEBI has approved IHH Healthcares open offer for acquisition of up to XX% stake in Fortis Healthcare. If materializes this should uplift IHHs holding in Fortis to 57%"  
[X Link](https://x.com/Generic_Tina/status/1976446401489064301) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-10T00:35Z XX followers, XX engagements


"Telix Pharmaceuticals reports 3Q25 revenue of $206M up XX% YoY and X% QoQ. The company raised 2025 revenue guidance to $800820M from $770800M indicating 4Q25 revenue of $288308M up XX% QoQ"  
[X Link](https://x.com/Generic_Tina/status/1978620753336770678) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-16T00:35Z XX followers, XX engagements


"Top Glove Corp's revenue grew XX% YoY to RM 3.5B in FY25 driven by a XX% increase in sales volume amid competitive pricing. Positive outlook on stock as margin improved alongside volume growth"  
[X Link](https://x.com/Generic_Tina/status/1978983108612624775) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-17T00:35Z XX followers, XX engagements


"Sumitomo Pharma partners with Knight Therapeutics for exclusive licensing agreements in Canada and with Novo Nordisk in Japan for co-promotion of Ozempic leading to positive stock performance"  
[X Link](https://x.com/Generic_Tina/status/1978661813551239638) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-16T03:18Z XX followers, XX engagements


"Hansoh granted Roche exclusive license for CDH17-targeting ADC HS-20110. CDH17 targeted drug development scene is crowded. Hansohs strong execution with Roches global prowess will give it an edge"  
[X Link](https://x.com/Generic_Tina/status/1980070267860009308) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-20T00:35Z XX followers, XX engagements


"Astellas Pharma's Izervay receives conditional approval in Japan for age-related macular degeneration. Izervay witnessed record high sales in Q1FY26 and a revenue growth of XX% is expected for FY26"  
[X Link](https://x.com/Generic_Tina/status/1973909683137282450) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-03T00:35Z XX followers, XX engagements


"Hansoh and Leads Biolabs bag global outlicensing deals. Chugais partner Lilly announced positive P3 result for orforglipron. Celltrion launched Actemra biosimilar in US"  
[X Link](https://x.com/Generic_Tina/status/1979707871999983865) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-19T00:35Z XX followers, XX engagements


"Bama Tea (BAMA HK) launched Hong Kong IPO. Bama specializes in tea leaf products in China. Pure volume play with branded offerings in a fragmented market. We would recommend to subscribe the issue"  
[X Link](https://x.com/Generic_Tina/status/1980432680786489760) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-21T00:35Z XX followers, XX engagements